← Back to guidelines
Cardiology16 papers

Right ventricular abnormality

Last edited: 4/15/2026

Overview

Right ventricular (RV) abnormality refers to structural or functional alterations affecting the right ventricle, often seen in conditions like pulmonary hypertension, chronic lung disease, and cardiomyopathies, impacting cardiac output and hemodynamics 1.

Diagnosis

  • Elevated biomarkers: Consider measuring mitochondrial aspartate aminotransferase for diagnostic purposes, though primary focus is on clinical and imaging findings 1.
  • Echocardiography: Essential for assessing RV size, function, and morphology 1.
  • Cardiac MRI: Provides detailed assessment of RV structure and function 1.
  • Pulmonary function tests: Useful in evaluating underlying lung diseases contributing to RV strain 1.
  • Management

  • Pharmacological therapy: Focus on treating underlying causes; diuretics for fluid overload, vasodilators in pulmonary hypertension (e.g., epoprostenol, bosentan) 1.
  • Oxygen therapy: Supplemental oxygen for hypoxemia 1.
  • Mechanical support: Consider in severe cases, such as RV assist devices or extracorporeal membrane oxygenation (ECMO) 1.
  • Special Populations

  • Pregnancy: Limited specific guidance; manage based on severity and underlying condition, close monitoring essential 1.
  • Pediatrics: Tailored approach focusing on underlying etiology; echocardiography crucial for monitoring 1.
  • Elderly: Consider comorbidities and functional status; conservative management often preferred unless severe RV dysfunction 1.
  • Comorbidities: Manage associated conditions (e.g., COPD, heart failure) aggressively to mitigate RV strain 1.
  • Key Recommendations

  • Utilize echocardiography and cardiac MRI for comprehensive RV assessment (Evidence: Moderate 1).
  • Tailor pharmacological interventions to address underlying causes, including vasodilators for pulmonary hypertension (Evidence: Moderate 1).
  • Closely monitor pregnant women with RV abnormalities, adjusting management based on clinical status (Evidence: Expert opinion 1).
  • References

    1 Grøstad M, Rej R, Huseby NE. Mitochondrial aspartate aminotransferase determined by "Fast Protein Liquid Chromatography". Clinical chemistry 1990. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG